Switching from Other Agents to Extended-Release Carbamazepine in Acute Mania
By Rif S. El-Mallakh, MD, Terence A. Ketter, MD, Richard H. Weisler, MD, Robert Hirschfeld, MD, Andrew J. Cutler, MD, Thomas Gazda, MD, Paul Keck, Jr, MD, Alan C. Swann, MD, and Amir H. Kalali, MD
The Effect of Food on the Absorption of Oral Ziprasidone
By Jeffrey J. Miceli, PhD, Paul Glue, MD, PhD, Jeffrey Alderman, PhD, and Keith Wilner, PhD
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia in Special Patient Populations
By Eduard Parellada, MD, MSc, PhD
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
Efficacy of Olanzapine and Risperidone in Schizophrenia:A Randomized Double-Blind Crossover Design
By Jose M. Canive, MD, Gregory A Miller, PhD, Jessica G. Irwin, BS, Sandra N. Moses, PhD, Robert J. Thoma, PhD, J. Christopher Edgar, PhD,
Andrea Sherwood, PhD, Fernando Torres, MD, Marianna LaNoue, PhD, Stephen Lewis, MD, Faith M. Hanlon, PhD, Michael P. Weisend, PhD,
Valerie Mead, MD, and Vicente B. Tuason, MD
Contacts
in Drug Disposition & Pharmacokinetics
|
Post a Comment